Divya Rajamohan
Current status of drug screening and disease modelling in human pluripotent stem cells
Rajamohan, Divya; Matsa, Elena; Kalra, Spandan; Crutchley, James; Patel, Asha; George, Vinoj; Denning, Chris
Authors
Elena Matsa
Spandan Kalra
James Crutchley
Asha Patel
Vinoj George
Professor CHRIS DENNING chris.denning@nottingham.ac.uk
PROFESSOR OF STEM CELL BIOLOGY
Abstract
The emphasis in human pluripotent stem cell (hPSC) technologies has shifted from cell therapy to in vitro disease modelling and drug screening. This review examines why this shift has occurred, and how current technological limitations might be overcome to fully realise the potential of hPSCs. Details are provided for all disease-specific human induced pluripotent stem cell lines spanning a dozen dysfunctional organ systems. Phenotype and pharmacology have been examined in only 17 of 63 lines, primarily those that model neurological and cardiac conditions. Drug screening is most advanced in hPSC-cardiomyocytes. Responses for almost 60 agents include examples of how careful tests in hPSC-cardiomyocytes have improved on existing in vitro assays, and how these cells have been integrated into high throughput imaging and electrophysiology industrial platforms. Such successes will provide an incentive to overcome bottlenecks in hPSC technology such as improving cell maturity and industrial scalability whilst reducing cost.
Citation
Rajamohan, D., Matsa, E., Kalra, S., Crutchley, J., Patel, A., George, V., & Denning, C. (2013). Current status of drug screening and disease modelling in human pluripotent stem cells. BioEssays, 35(3), https://doi.org/10.1002/bies.201200053
Journal Article Type | Article |
---|---|
Publication Date | Mar 1, 2013 |
Deposit Date | Apr 15, 2014 |
Publicly Available Date | Apr 15, 2014 |
Journal | BioEssays |
Print ISSN | 0265-9247 |
Electronic ISSN | 1521-1878 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 35 |
Issue | 3 |
DOI | https://doi.org/10.1002/bies.201200053 |
Keywords | Automation, Cardiomyocytes, Drug safety assessment, Human embryonic stem cells, Human induced pluripotent stem cells |
Public URL | https://nottingham-repository.worktribe.com/output/1002711 |
Publisher URL | http://onlinelibrary.wiley.com/doi/10.1002/bies.201200053/abstract |
Files
Denning_Current_status_of_drug_screening.pdf
(290 Kb)
PDF
Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0
You might also like
SnoRNAs in cardiovascular development, function, and disease
(2024)
Journal Article
‘Project period’: a workplace health promotion innovation in a higher education setting
(2023)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search